NewLimit Raises $435M for Aging Medicines

So excited for NewLimit's (Boost VC port co) $435M Series C round led by Founders Fund! Their recent results are so promising for expanding human life, more breakthroughs coming soon... Jacob Kimmel, Brian Armstrong and the whole NewLimit team are changing how we think about health altogether.

🎯 How a Welsh Oncology Company Raised 7 Figures — Without a Single VC. In April 2026, Awen Oncology closed a 7-figure private funding round. No venture capital. No pitch competitions. No cold outreach. Just warm, curated introductions to the right investors — at the right time. Here's what our Business Development service actually looked like for Awen: ✅ A dedicated BD Manager assigned from day one ✅ A bespoke investor brief built around their oncology story ✅ Direct introductions to pre-qualified HNWIs, UHNWIs & Family Offices across Europe and the UK — investors who already understood the space ✅ Weekly strategy calls to refine messaging and track investor responses ✅ A 7-figure close in under 90 days from first introduction This is what capital introduction looks like when it's done properly. Not a database. Not a platform. A network — built on relationships, operated by people who understand healthcare investment. If your company is raising in 2026 and you're still relying on cold outreach or waiting for a VC to call back — there's a better way. 📩 Applications are now open for Q2/Q3 2026. 🔗 https://lnkd.in/eRjeamVQ #HealthcareInvestment #Oncology #PrivateFunding #HNWI #FamilyOffice #DONHealthcareNetwork #AwendOncology #MedTech #CapitalIntroduction #HealthcareStartups #Biotech

Bay Area Lyme Ventures, the impact investment fund created by Bay Area Lyme Foundation, is proud to announce a strategic investment in Galaxy Diagnostics, Inc., a leader in advanced testing for Lyme disease and other vector-borne illnesses. This investment reflects our commitment to accelerating the development and commercialization of innovative diagnostics that can help patients get answers sooner. For too long, individuals with tick-borne diseases have faced delayed diagnoses, limited testing options, and prolonged uncertainty. Galaxy Diagnostics has built a strong reputation for advancing cutting-edge molecular and antigen detection technologies, translating scientific discoveries into clinically meaningful tools. The company is also helping advance promising research funded by Bay Area Lyme Foundation, including groundbreaking work on Borrelia peptidoglycan antigen detection. As the first venture philanthropy fund dedicated to Lyme disease solutions, Bay Area Lyme Ventures was created to bridge the gap between research and patient access—helping breakthrough diagnostics and therapeutics reach the people who need them most. Read more: https://lnkd.in/gMsYaTZN #LymeDisease #TickBorneDisease #Diagnostics #MedicalInnovation #Biotechnology #ImpactInvesting #BayAreaLymeVentures

Congratulations to IMU Biosciences on their latest financing round. “When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could unlock something genuinely transformative in precision medicine. Our participation in this round reflects what we've seen since: a team that executes and a platform that delivers. The immune system sits at the heart of almost every disease; a company that can interrogate it at this resolution has the potential to redefine how we match the right treatment to the right patient at the right time. We're proud to be IMU's largest shareholder and delighted to welcome IQ Capital and the British Business Bank as investors to the round, their support is a further corroboration of what IMU is building. We're excited about what comes next.” Partner, Inga Deakin

Fantastic news and valuable perspective. The centrality of the immune system touches so many diseases and therapies. Measuring the right proteins, longitudinally and at scale, can help connect molecular signals to immune state, disease trajectory and therapeutic response. It gives us a practical way to move from broad biological data capture toward clinically actionable insight. Personalized medicine demands the full and dynamic context of the body, not just a single snapshot in time. Congratulations to IMU Biosciences.

For decades, the immune system has been measured with tools too blunt for its complexity, despite having a major role in many diseases. IMU Biosciences changes the resolution. Its platform resolves ~2,500 immune cell subsets from 2ml of blood, turning a routine sample into one of the richest immune readouts available. The team is applying this to areas where current tools are inadequate - like predicting whether a stem cell graft will take, whether a transplanted organ will be rejected, or whether a patient will respond to cancer immunotherapy. We're proud to co-lead IMU's $53m Series A alongside Molten Ventures. Congratulations to John Baker and the whole IMU team - excited to support what comes next.

We’re delighted to announce the successful completion of an oversubscribed financing round which has bought our total Series A funding to over $53 million (£40 million). The additional funding will be used to scale our operations, develop our clinical platform and infrastructure, and advance our clinical programmes, delivering on our vision to fundamentally change how we understand, diagnose, and treat disease. We’re grateful for the support from our co-lead investors, Molten Ventures, IQ Capital and as well as The British Business Bank, Meltwind Advisory LLP and our existing investors as we progress our work to decode the immune system with unprecedented resolution and scale. Read the full press release on our website here: https://lnkd.in/eRCd_uUs #Fundraising #Biotech #Immunology #Innovation #PrecisionMedicine #IMUBiosciences

Great news from IMU Biosciences today with $53m for high-definition interrogation of the immune system, at unprecedented resolution and scale. In the last few decades, we have more tools to capture biological data, from genomics and proteomics at the sub/cellular level, tissue biopsy, organ function, all the way up to whole body physiology and behaviour, but what is the context? Mutimodal is exciting, but if you're not looking at the immune system, you're missing a key contributor/responder/driver of disease, across nearly every therapeutic area. This is true personalised medicine; not just the genes you were born with, but the full context of your body, what is has experienced before, where it is now, and predicting the future. It is a thrill to work with Adam Laing, John Baker, Tom Hayday, Mario Cantero, Tim Haines and the whole IMU team. Welcome to Alex Wilson and Kushaal Desai at IQ Capital, Carmine Circelli and Jemma Day at British Business Bank and Jonathan Milner and Mike Murphy at Meltwind Advisory LLP, super partners to support this amazing company, with Molten Ventures. A category defining company for biology and health. See link in comments for Adam's eloquent blog on the new website

Excited to continue Molten's support for IMU in their work to deepen the understanding of the immune system. Using high definition interrogation with the world's largest immune dataset, IMU are producing unprecedented insights for patients and healthcare providers

I was wowed by IMU Biosciences presentation at our Molten investor day in February - literally life changing technology! So we are really pleased about the latest financing round of $53m to decode the immune system in high‑definition. A category‑defining company shaping the future of personalised medicine!